Alzamend Neuro is trading 5.5% up at $1.53, with no clear August 14, 2026 company-specific catalyst identified.
- Recent coverage highlights an August 4 financing, updated August 12.
- Alzamend received $7.5 million and secured access to up to $17.5 million in additional funding.
- Available sources do not directly link the financing announcement to the current move.